It is very nice to visit Lambda facility and thanks to warm welcome provided by all the teams. I can easily say one of the best CRO I ever visited. People here are wonderful and doing great job

Reputed Client of Israel

Awesome hospitality & fantastic office. All the best!

Reputed Client of Japan

Excellent hospitality and cooperation received throughout the audit. People are knowledgeable and extremely transparent. Looking for long time relation

Reputed Client of Asia

Facility is too good to conduct the BABE studies and adherence to protocol and quality assurance in conducting studies are meeting sponsor expectations and requirements.

Reputed Client of India

Facility is good, people r trained well and know the subject on which they r working. All the best.

Reputed Client of USA

Highly innovative and advanced research centre that possess bright future for the development of the country.

Reputed International Government Body

It is one of the best facility in India for BA/BE

Reputed Regulatory Authority

Lambda is a very professional CRO. All the staff here are experienced and very knowledgeable. I'm grateful for their accommodations and hospitality. The future, if we want to carry out BE study, we will ask Lambda help again.

Reputed Client of Europe

It was a really pleasant meeting with the PV department, and I am looking forward to the next visit.

Reputed Client of Europe

Amazing and best CRO I ever seen

Reputed Client of China

Company News

Company News

Home / Company News

Lambda Therapeutic Research Ltd, organised the 2nd Annual Symposium on "Oncology - New Horizons"

16 Aug 2016

As a part of its corporate social responsibility initiative, Lambda had organized a symposium dedicated to oncology titled 'Oncology - New Horizons'. It was an event built around knowledge sharing and understanding the latest advances and newer modalities of treatments amidst some of the leading cancer treatment centers and top oncologists/clinicians across the world.

Oncology was the focus point of the symposium as it is one of the leading maladies across the world and in India in particular. Its occurrence is growing year on year globally and, hence there is a dire need to have a focussed approach in treatment modalities and continuous research to make therapy affordable, especially in developing countries like India. Latest advances from a global perspective like novel immunotherapies, newer Biomarkers for early detection, screening modalities and more were discussed, which were of immense benefit to practising oncologists in India for betterment of their patients' lives.

Envisioned by their Managing Director - Mrs. Bindi Chudgar, the two-day long symposium, scheduled on 21st and 22nd February 2014 and hosted at Lambda's state-of-the-art facilities in Ahmedabad, had a strong international participation from guest speakers from USA and UK, eminent oncologists from well-known centers across India, and of course senior scientists from the Indian pharmaceutical industry. Inaugurated by Mr. D G Shah - Secretary General, IPA and Dr Pankaj Shah, well-known hematologist and ex-director GCRI, there was a valuable sharing experience.

Among the many distinguished speakers were Padmashri Dr. Ashok Vaid, Chairman Oncology from Medanta Cancer Institute who spoke on 'Management approach in Lung Cancer', Dr. Mahesh Desai, Medical Director from MPUH, Nadiad who elaborated on 'Partial Nephrectomy in Kidney Tumours' , Dr. Vamsidhar Velcheti from Cleaveland Clinic, US and Dr. Karthik Ramasamy from Oxford University, UK who gave a different and additional view of their experiences in the US and UK in treating the most difficult malady of the world.

It was a hugely successful event and was well appreciated by the oncology fraternity from across the globe, setting benchmarks in the CRO industry.

Lambda Therapeutic Research, under the strong and able leadership of Mrs. Bindi Chudgar, their Managing Director, today has emerged as a global multinational CRO, offering varied services spread across the clinical research spectrum like BA/BE studies, multi-therapeutic clinical trials including oncology, medical imaging, and pharmacovigilance. As India's largest CRO, Lambda has spread its operations and built world class, state-of-the-art infrastructure in North America, the United Kingdom, Europe, South East Asia and India.

For more information please visit: http://transfer.sarjen.com/lambda-cro.com/ Primary Media Contact: Pritesh Trivedi, priteshtrivedi@oneadvt.com, 91-97272-60309 Secondary Media Contact: Gaurang Darji, gaurangdarji@oneadvt.com, 91-99250-38960

The above Press Release in its entirety was widely reported in the media in several Newspapers and print publications including and not limited to India Today, Headlines India, Life Sciences Industry News, Pharma Focus Asia, PR Newswire India, Press Trust of India, The Pharma Times, ZeeNews (India) etc.